Skip to main content

Table 2 Clinicopathological factors in patients with peritoneal metastases from colorectal cancer

From: The prognostic impact of lead times in colorectal cancer patients undergoing cytoreductive surgery and HIPEC

Factor

n = 148

%

Age (median 66 years)

 < 66 years

73

49.3

 ≥ 66 years

75

50.7

Gender

 Women

95

64.2

 Men

53

35.8

Timing of CPM

 Synchronous CPM

73

49.3

 Metachronous CPM

75

50.7

Location of primary tumour

 Rectum

15

10.1

 Left colon

52

35.1

 Right colon

80

54.1

 Data missing

1

0.7

Preoperative laparotomy or laparoscopy

 Yes

53

35.8

 No

95

64.2

Reason for prolonged time to decision for surgery

 Tumor investigation

142

95.9

 Medical investigation of patient factors

1

0.7

 Other

5

3.4

Type of surgery

 CRS + HIPEC

106

71.6

 CRS

13

8.8

 Open-close

29

19.6

HIPEC regime

 Oxaliplatin

89

59.5

 Irinotecan

14

9.5

 Mitomycin C

3

2

PCI score

 PCI ≤ 20

102

68.9

 PCI ≥ 21

40

27

 Data missing

6

4.1

Cytoreduction score

 CC0

106

71.6

 CC1

11

7.4

 CC2

1

0.7

 CC3

29

19.6

 Data missing

1

0.7

Clavien-Dindo grade

 Grade I–II

109

73.6

 Grade III–IV

37

25

 Dead

2

1.4

Liver metastases

 Yes

16

10.8

 No

132

89.2

Signet ring cells

 Yes

28

18.9

 No

118

79.7

 Data missing

2

1.4

BRAF mutation

 Yes

10

6.8

 No

62

41.9

 ND

76

51.4

KRAS mutation

 Yes

35

23.6

 No

38

25.7

 ND

75

50.7

Adjuvant treatment

 Yes

58

39.2

 No

87

58.8

 Data missing

3

2

  1. CPM colorectal cancer and peritoneal metastases, ND not done